Cymbalta gets support for broader use
The pressure of Eli Lilly’s looming patent cliff has beenreduced after a US Committee has recommended expanding the pain indication forits top selling drug Cymbalta (duloxetine HCL).
Read MoreAuthor: Katrina Megget
Date rape drug being considered by FDA
Despite GHB being a popular date rape drug, the US Food andDrug Administration has revealed it believes it to be effective in treatingfibromyalgia, say documents released ahead of today’s marketing review.
Read MoreCancer code cracked
The move towards personalised medicine has catapulted forward after UK scientists identified all mutations in skin and lung cancer and produced the first complete cancer genomes.
Read MoreTriCor and Adderall lawsuits settled
Teva Pharmaceuticals has reached settlements in two massive lawsuits.
Read MoreRoche’s diabetes drug tops rival Januvia
Roche and Ipsen’s investigational type 2 diabetes drug taspoglutide has inched its way ahead of rival Merck’s Januvia, according to late stage studies.
Read More- Lundbeck to present new Vyepti and bocunebart data at EAN 2026
- Agomab outlines design of phase 2b NOV‑ERA study in fibrostenosing Crohn’s disease
- Pierre Fabre wins EC approval for Braftovi regimen in BRAFV600E‑mutant mCRC
- Cenrifki approved in EU for secondary progressive multiple sclerosis
- NICE backs daratumumab quadruplet for newly diagnosed transplant‑ineligible myeloma
